Drugs Containing Excipient (Inactive Ingredient) POLYOXYL 40 CASTOR OIL

Branded drugs containing POLYOXYL 40 CASTOR OIL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	TRAVATAN Z	travoprost	0065-0260	POLYOXYL 40 CASTOR OIL
Physicians Total Care Inc	TRAVATAN Z	travoprost	54868-5968	POLYOXYL 40 CASTOR OIL

Generic drugs containing POLYOXYL 40 CASTOR OIL excipient

Company	Ingredient	NDC	Excipient
Alcon Laboratories Inc	travoprost	0065-0260	POLYOXYL 40 CASTOR OIL
Endo USA Inc	felodipine	0603-3581	POLYOXYL 40 CASTOR OIL
Physicians Total Care Inc	travoprost	54868-5968	POLYOXYL 40 CASTOR OIL

Polyoxyl 40 Castor Oil Market Dynamics, Financial Trajectory, Suppliers, and Pharmaceutical IP

Last updated: August 2, 2026

Polyoxyl 40 castor oil is a nonionic surfactant excipient used to improve solubility, dispersion, emulsification, and bioavailability in pharmaceutical formulations. Its commercial outlook is tied to growth in poorly water-soluble drugs, lipid-based delivery systems, injectable formulations, and formulation development outsourcing. The market is fragmented and private-company dominated, so standalone revenue, market share, and profitability figures are generally not disclosed. Financial performance is best assessed through demand from pharmaceutical excipients, specialty chemicals, and drug-delivery technologies rather than through a separately reported product line.

What is polyoxyl 40 castor oil used for in pharmaceuticals?

Polyoxyl 40 castor oil is a polyoxyethylene derivative of castor oil used as a solubilizer, emulsifier, wetting agent, and surfactant. It is associated with the broader class of polyoxylated castor oils and hydrogenated castor oils.

The nomenclature requires care:

Commercial or regulatory name	Typical description	Market relevance
Polyoxyl 40 hydrogenated castor oil	Polyoxyethylene derivative of hydrogenated castor oil	Commonly associated with macrogolglycerol hydroxystearate 40 and products such as Kolliphor RH 40
Polyoxylated castor oil	Polyoxyethylene derivative of non-hydrogenated castor oil	Often associated with Cremophor EL-type materials
Macrogolglycerol hydroxystearate 40	European Pharmacopoeia-style terminology	Used in pharmaceutical formulation and regulatory documentation
PEG-40 hydrogenated castor oil	Common technical and cosmetic terminology	May refer to materials with different specifications depending on supplier and market
Cremophor RH 40	BASF trade name	A widely recognized commercial product for pharmaceutical formulation

The exact material identity, hydroxyl value, ethylene oxide distribution, free polyethylene glycol content, water content, acid value, and residual impurities can affect formulation performance and regulatory acceptability. Buyers should not treat all PEG-40 castor oil products as interchangeable.

How large is the polyoxyl 40 castor oil market?

No major supplier publicly reports polyoxyl 40 castor oil revenue as a separate business line. Public market reports usually combine it with pharmaceutical surfactants, solubilizers, lipid excipients, polyoxyethylene derivatives, or specialty excipients. Standalone market-size estimates therefore have limited auditability.

The addressable market has four principal demand pools:

1. Pharmaceutical excipient sales.
2. Drug-delivery and lipid-formulation development.
3. Commercial drug products using polyoxyethylated castor oil or related surfactants.
4. Cosmetic, nutraceutical, and personal-care applications.

Pharmaceutical demand is smaller than total castor-oil derivative demand but has higher qualification barriers and stronger pricing than commodity applications. A supplier that sells a compendial, GMP-manufactured grade can earn a premium over industrial or cosmetic material.

Public industry data support the underlying demand drivers. Poor aqueous solubility remains a major formulation problem, and lipid-based systems use surfactants and cosurfactants to improve drug dissolution and absorption (Pouton, 2000; Williams et al., 2013). FDA’s Inactive Ingredient Database also confirms the regulatory use of excipients across approved drug products, although the database does not provide product-level excipient revenue or market-share data (U.S. Food and Drug Administration, n.d.-a).

What is driving demand for polyoxyl 40 castor oil?

Poorly soluble active pharmaceutical ingredients

A large share of drug candidates has limited aqueous solubility. Polyoxyl 40 castor oil can support micellar solubilization, emulsification, and self-emulsifying drug-delivery systems. Its value is highest when it enables a viable dosage form or reduces the amount of another solvent or cosolvent.

Demand is strongest in:

• Oral soft-gel and liquid formulations.
• Self-emulsifying and nanoemulsion systems.
• Lipid-based formulations.
• Certain injectable and concentrated drug products.
• Topical and ophthalmic delivery systems.
• Reformulations intended to improve bioavailability or reduce pill burden.

Generic-drug reformulation

Generic manufacturers use established excipients to reproduce reference-product performance, develop alternative dosage forms, and address manufacturing or supply constraints. Polyoxylated castor oil can be relevant where the reference product uses a solubilizing surfactant or where a generic formulation requires improved dissolution.

The commercial opportunity is larger for a qualified grade with a reliable regulatory package than for an unqualified low-cost material. A supplier’s drug-master-file support, change-control system, impurity profile, and batch consistency can determine whether a formulation developer adopts the product.

Biopharmaceutical and specialty delivery systems

Polyoxylated surfactants are used in some protein, peptide, and specialty delivery contexts, but product selection is highly molecule-specific. Polyoxyl 40 castor oil should not be treated as a universal substitute for polysorbate 20, polysorbate 80, poloxamers, or polyethylene glycol-based surfactants. Oxidation, hydrolysis, extractables, leachables, and compatibility with proteins or container systems must be evaluated.

Regional pharmaceutical manufacturing

Growth in pharmaceutical manufacturing capacity in India, China, Southeast Asia, and other emerging production centers supports demand for qualified excipients. Local manufacturers often seek dual sourcing, lower landed cost, and regionally available compendial materials. Suppliers that can provide technical support and regulatory documentation have an advantage over traders selling undifferentiated material.

Which companies supply polyoxyl 40 castor oil?

The supply base includes multinational specialty-chemical companies, regional excipient manufacturers, and distributors. Commonly encountered commercial sources include:

Supplier or brand	Relevant product or capability	Commercial position
BASF	Kolliphor RH 40 and related pharmaceutical solubilizers	Global specialty-excipient supplier with formulation support
Nikko Chemicals	HCO-40 and related hydrogenated castor oil derivatives	Established Japanese supplier with pharmaceutical and personal-care exposure
Croda	Specialty excipients and surfactants	Broad pharmaceutical excipient portfolio and formulation expertise
Gattefossé	Lipid excipients and drug-delivery technologies	Strong position in lipid-based formulation development
Regional manufacturers	PEG-40 castor oil and hydrogenated castor oil grades	Price competition, local supply, and regional regulatory support
Distributors	Multiple branded and private-label grades	Inventory and geographic access rather than primary manufacturing

Commercial availability does not establish pharmaceutical equivalence. A supplier may sell a product under a chemically similar name that lacks the same compendial status, impurity limits, or regulatory history.

What formulations are protected by polyoxyl 40 castor oil patents?

Polyoxyl 40 castor oil itself is an established excipient class rather than a newly invented active pharmaceutical ingredient. Basic composition patents covering common polyoxyethylated castor oil materials are generally old and do not create a modern, broad exclusivity barrier around routine use.

Patent value usually resides in the formulation or manufacturing context:

• Specific drug-excipient ratios.
• Concentrated injectable solutions.
• Self-emulsifying drug-delivery systems.
• Nanoemulsions and microemulsions.
• Solid dispersions or adsorbed lipid systems.
• Stabilized formulations with defined antioxidant systems.
• Container-closure systems that limit extractables or oxidation.
• Manufacturing processes that control particle size, droplet size, or viscosity.
• Particular therapeutic uses or dosing regimens.

A patent search must therefore begin with the active ingredient, dosage form, route of administration, and assignee. Searching only “polyoxyl 40 castor oil” will miss patents that claim the excipient generically as “a nonionic surfactant,” “a polyoxyethylene castor oil derivative,” or “a hydrogenated castor oil ethoxylate.”

How strong is the patent estate for polyoxyl 40 castor oil?

The standalone patent estate is weak as a barrier to material substitution because:

• The chemical class has been commercially used for decades.
• Multiple suppliers offer related grades.
• Patent claims may cover broad surfactant classes rather than a single supplier’s product.
• Pharmaceutical customers can sometimes replace the excipient after comparative formulation work.
• Regulatory exclusivity generally attaches to the drug product, not to the excipient.

The stronger protection lies in manufacturing know-how and customer qualification. A supplier may protect:

• Ethoxylation conditions.
• Removal of residual reactants.
• Control of molecular-weight distribution.
• Hydrogenation and purification steps.
• Low-peroxide or low-aldehyde specifications.
• Batch-release testing.
• Scale-up methods.
• Proprietary mixtures optimized for a particular formulation.

These protections may be difficult to reproduce even when no enforceable patent blocks competition. Trade secrets, process control, customer-specific specifications, and regulatory history can create practical switching costs.

Does polyoxyl 40 castor oil have Orange Book listings or Paragraph IV challenges?

No. Polyoxyl 40 castor oil is an inactive pharmaceutical ingredient, not an active drug product. It does not have its own FDA Orange Book listing, FDA marketing exclusivity period, or standalone Paragraph IV challenge pathway.

Paragraph IV litigation concerns patents listed for an approved drug product in the FDA Orange Book. A generic applicant may challenge patents covering a formulation that contains polyoxylated castor oil, but the challenge targets the drug product’s listed patent claims, not the excipient as an independent product (U.S. Food and Drug Administration, n.d.-b).

Relevant legal exposure can arise in three ways:

1. A drug patent claims a formulation containing polyoxyl 40 castor oil.
2. A supplier’s product is alleged to induce or contribute to infringement by a customer.
3. A customer relies on a formulation patent that limits substitution with another surfactant.

These risks are formulation-specific and cannot be inferred from the excipient name alone.

When does polyoxyl 40 castor oil lose exclusivity?

Polyoxyl 40 castor oil has no single market-wide patent-expiration date. The underlying material is an established excipient, so commercial competition already exists. Exclusivity may instead attach to:

• A supplier-specific product specification.
• A process patent.
• A drug formulation patent.
• A method-of-use patent.
• A customer contract or preferred-supplier agreement.
• A regulatory filing that supports a particular grade.

For drug products, U.S. patent expiry depends on the Orange Book-listed patents and patent-term adjustments or extensions. For excipient suppliers, the relevant patent family must be reviewed by jurisdiction, priority date, legal status, and claim scope. A material can remain commercially differentiated after patent expiry if the supplier retains manufacturing scale, qualification records, and customer approvals.

What is the FDA regulatory status of polyoxyl 40 castor oil?

FDA treats excipients through the finished drug approval process rather than granting them independent premarket approval as active ingredients. A manufacturer must demonstrate that the excipient is suitable for its proposed use, concentration, route, and dosage form.

Key regulatory tools include:

• The FDA Inactive Ingredient Database.
• USP-NF monographs where applicable.
• Drug Master Files.
• Supplier qualification packages.
• Extractables and leachables assessments.
• Stability and compatibility studies.
• Toxicological and impurity assessments.
• Change-control commitments.

The FDA Inactive Ingredient Database can support precedent analysis, but prior use does not automatically establish acceptability for a new route, concentration, or patient population. Parenteral use generally receives greater scrutiny than oral use because of exposure, hypersensitivity, sterility, and excipient safety concerns.

The European market may use Ph. Eur. terminology such as macrogolglycerol hydroxystearate 40. A supplier seeking global adoption must align USP-NF, Ph. Eur., JP, and customer-specific specifications where relevant.

What safety issues affect commercial demand?

Polyoxyethylated castor oil products have been associated with hypersensitivity and infusion-related reactions in certain injectable drug formulations. The clinical risk is product- and route-dependent, and it should not be generalized across all polyoxylated castor oil grades.

Important development considerations include:

• Hypersensitivity and anaphylactoid reactions.
• Oxidative degradation.
• Peroxide and aldehyde formation.
• Interaction with proteins and biologics.
• Container-closure compatibility.
• Residual ethylene oxide or related process impurities.
• Batch-to-batch molecular-weight variation.
• Effects on drug release and absorption.

These concerns create a mixed market effect. They can limit use in injectable products, but they also increase demand for better-characterized grades, lower-impurity materials, alternative surfactants, and formulation redesign.

How does polyoxyl 40 castor oil compare with competing excipients?

Excipient class	Main advantage	Main limitation	Competitive relationship
Polyoxyl 40 castor oil	Strong solubilization and emulsification	Safety, oxidation, and compatibility concerns	Selected when solubilizing capacity outweighs risk
Polysorbate 80	Broad use in biologics and injectables	Oxidation and hydrolysis; fatty-acid variability	Frequent substitute or comparator
Polysorbate 20	Useful for proteins and formulations requiring a different fatty-acid profile	May provide different solubilization performance	Alternative in selected biologic and liquid products
Poloxamer 188	Protein stabilization and surfactant functionality	Different hydrophilic-lipophilic balance and performance	Competes in biologics and parenteral development
PEG-based solubilizers	Established chemistry and broad formulation use	May alter viscosity, tolerability, or drug release	Used when polyoxylated castor oil is unsuitable
Vitamin E TPGS	Solubilization and potential absorption enhancement	Cost and formulation-specific regulatory considerations	Competes in oral lipid-based systems
Phospholipids and lipid blends	Strong fit for lipid nanoparticles and emulsions	More complex sourcing and processing	Compete in advanced delivery systems

Substitution is rarely a simple one-for-one procurement decision. Changing the surfactant can alter dissolution, particle size, bioavailability, viscosity, preservative performance, stability, and regulatory comparability.

What is the financial trajectory for polyoxyl 40 castor oil?

The likely financial trajectory is moderate volume growth with margin differentiation by grade, geography, and regulatory support.

Near-term outlook

Demand should remain supported by:

• Continued development of poorly soluble compounds.
• Generic reformulation and lifecycle management.
• Growth in oral lipid formulations.
• Expansion of pharmaceutical manufacturing in Asia.
• Use of qualified excipients in contract development and manufacturing.

Price growth is less certain. Castor oil derivatives face raw-material and energy-cost exposure, while multiple suppliers limit the ability to pass through costs in standard grades.

Medium-term outlook

Higher-value growth is more likely in:

• Low-impurity pharmaceutical grades.
• Injectable-compatible materials.
• Custom surfactant blends.
• Regulatory support and formulation services.
• Excipient packages for self-emulsifying systems.
• Products with validated oxidative stability.

Standard PEG-40 castor oil grades used in cosmetics and industrial applications are more exposed to price competition. Pharmaceutical-grade materials can maintain higher margins because supplier changes trigger formulation, stability, regulatory, and validation work.

Long-term risks

The main structural risks are:

• Substitution by polysorbates, poloxamers, phospholipids, or vitamin E TPGS.
• Safety-driven reformulation of injectable products.
• Consolidation among pharmaceutical excipient buyers.
• Customer insourcing or dual sourcing.
• Raw-material volatility.
• Regulatory tightening on impurities and oxidation products.
• Loss of demand if a major drug product is discontinued or reformulated.

BASF and other specialty-chemical companies report pharmaceutical excipients within broader business segments, preventing direct attribution of revenue or operating margin to individual products (BASF SE, 2024). The same limitation applies to other diversified suppliers.

What generic launch risks exist for drugs containing polyoxyl 40 castor oil?

Generic entry risk depends on the finished drug product, not on the presence of the excipient alone. The principal issues are:

• Whether the reference formulation requires the same surfactant.
• Whether the generic applicant can demonstrate bioequivalence.
• Whether the product is a complex dosage form.
• Whether formulation patents remain enforceable.
• Whether the supplier has adequate inventory and dual-source capacity.
• Whether the excipient affects critical quality attributes.
• Whether the FDA requires comparative in vitro or in vivo testing.

For conventional oral products, excipient substitution may be feasible. For emulsions, injectables, long-acting systems, and complex lipid formulations, substitution can create significant development and regulatory work.

What licensing deals and settlement agreements affect the market?

Polyoxyl 40 castor oil itself is not generally commercialized through publicly disclosed licensing deals. Public agreements are more likely to concern:

• A drug formulation using the excipient.
• A lipid-delivery platform.
• A branded supplier’s distribution rights.
• A contract manufacturing or preferred-supplier arrangement.
• Patent settlements involving a finished drug.

Because excipient suppliers rarely disclose customer-specific contracts, licensing revenue and settlement economics cannot be assigned reliably to the material. The relevant commercial value is usually embedded in supply agreements, technical-service relationships, and formulation platform partnerships.

What geographic markets are most important?

North America and Europe remain important for regulated pharmaceutical-grade demand, documentation, and high-value formulation development. Asia is critical for volume growth, generic manufacturing, and local production capacity.

Region	Main opportunity	Main risk
United States	Complex generics, specialty injectables, CDMO demand	Stringent regulatory and customer qualification requirements
Europe	Ph. Eur. adoption and advanced formulation development	Fragmented national procurement and regulatory expectations
China	Domestic pharmaceutical production and local excipient supply	Price competition and qualification variability
India	Generic drugs, export manufacturing, and formulation development	Strong procurement pressure and supplier substitution
Japan	High-quality specialty excipients and established formulation expertise	Mature market and demanding specifications
Latin America and other emerging markets	Growing medicine production and import substitution	Registration, logistics, and currency risk

Key Takeaways

• Polyoxyl 40 castor oil is a pharmaceutical solubilizer and surfactant, not an active drug.
• Exact identity matters because polyoxyl 40 hydrogenated castor oil, polyoxyethylated castor oil, and PEG-40 castor oil are related but not necessarily interchangeable.
• No standalone public revenue or market-share data are available for the ingredient.
• Demand is linked to poorly soluble drugs, lipid formulations, generics, and pharmaceutical manufacturing growth.
• The excipient has no independent Orange Book listing, FDA exclusivity period, or Paragraph IV pathway.
• Patent barriers are generally formulation-specific; manufacturing know-how and regulatory qualification are stronger practical barriers.
• Pharmaceutical-grade suppliers can earn a premium through GMP controls, low-impurity specifications, documentation, and technical support.
• Safety, oxidation, compatibility, and injectable-use concerns create both substitution risk and demand for higher-quality grades.
• The most defensible financial outlook is moderate growth in qualified pharmaceutical grades, with weaker pricing power in standard cosmetic and industrial grades.

FAQs About Polyoxyl 40 Castor Oil

Is polyoxyl 40 castor oil the same as Cremophor EL?

No. Cremophor EL is generally associated with polyoxyethylated castor oil, while Cremophor RH 40 is associated with polyoxyethylated hydrogenated castor oil. Product specifications and regulatory identities must be checked before substitution.

Can polyoxyl 40 castor oil be used in injectable drugs?

It can be used in selected injectable formulations, but route-specific safety, impurity, compatibility, and hypersensitivity assessments are required. Prior use in one injectable product does not automatically establish suitability for another.

Is polyoxyl 40 castor oil listed in the FDA Inactive Ingredient Database?

The FDA database contains inactive-ingredient records for excipient names and related substances, but the result must be evaluated by route, dosage form, maximum potency, and nomenclature. A database entry is not a universal approval for every use.

What excipient can replace polyoxyl 40 castor oil?

Potential alternatives include polysorbates, poloxamers, PEG-based solubilizers, phospholipids, and vitamin E TPGS. The appropriate replacement depends on the active ingredient, route, concentration, stability profile, and bioequivalence requirements.

Does a supplier need a patent to sell pharmaceutical-grade polyoxyl 40 castor oil?

No. Sale generally depends on manufacturing controls, quality specifications, regulatory documentation, customer qualification, and applicable local requirements. Patent ownership is not required to commercialize an established excipient.

References

BASF SE. (2024). BASF report 2023. BASF.

Pouton, C. W. (2000). Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and “self-microemulsifying” drug delivery systems. European Journal of Pharmaceutical Sciences, 11(Suppl. 2), S93-S98. https://doi.org/10.1016/S0928-0987(00)00167-6

U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

United States Pharmacopeia. (2024). USP-NF general chapters and excipient monographs. United States Pharmacopeial Convention.

Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013). Strategies to address low drug solubility in discovery and development. Pharmacological Reviews, 65(1), 315-499. https://doi.org/10.1124/pr.112.005660